These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 7655780

  • 1. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
    Lissoni P, Barni S, Fossati V, Ardizzoia A, Cazzaniga M, Tancini G, Frigerio F.
    Support Care Cancer; 1995 May; 3(3):194-7. PubMed ID: 7655780
    [Abstract] [Full Text] [Related]

  • 2. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P, Bolis S, Brivio F, Fumagalli L.
    Anticancer Res; 2000 May; 20(3B):2103-5. PubMed ID: 10928160
    [Abstract] [Full Text] [Related]

  • 3. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
    Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Meregalli S, Fossati V, Fumagalli L, Brivio F, Tancini G.
    Oncology; 1995 May; 52(3):243-5. PubMed ID: 7715908
    [Abstract] [Full Text] [Related]

  • 4. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, Emanuelli G, Alderi G, Lavorato F.
    J Biol Regul Homeost Agents; 1995 May; 9(1):31-3. PubMed ID: 8553906
    [Abstract] [Full Text] [Related]

  • 5. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G.
    Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
    [Abstract] [Full Text] [Related]

  • 6. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
    Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R.
    Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
    [Abstract] [Full Text] [Related]

  • 7. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
    Lissoni P, Barni S, Rovelli F, Brivio F, Ardizzoia A, Tancini G, Conti A, Maestroni GJ.
    Eur J Cancer; 1993 Jan; 29A(2):185-9. PubMed ID: 8422280
    [Abstract] [Full Text] [Related]

  • 8. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, Colciago M, Rovelli F.
    Anticancer Res; 2008 Jan; 28(2B):1377-81. PubMed ID: 18505083
    [Abstract] [Full Text] [Related]

  • 9. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P, Fumagalli L, Paolorossi F, Rovelli F, Roselli MG, Maestroni GJ.
    J Biol Regul Homeost Agents; 1997 Jan; 11(3):119-22. PubMed ID: 9498162
    [Abstract] [Full Text] [Related]

  • 10. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.
    Aldeghi R, Lissoni P, Barni S, Ardizzoia A, Tancini G, Piperno A, Pozzi M, Ricci G, Conti A, Maestroni GJ.
    Eur J Cancer; 1994 Jan; 30A(2):167-70. PubMed ID: 8155391
    [Abstract] [Full Text] [Related]

  • 11. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
    Lissoni P, Tisi E, Barni S, Ardizzoia A, Rovelli F, Rescaldani R, Ballabio D, Benenti C, Angeli M, Tancini G.
    Br J Cancer; 1992 Jul; 66(1):155-8. PubMed ID: 1322155
    [Abstract] [Full Text] [Related]

  • 12. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
    Lissoni P, Mandalà M, Brivio F.
    Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status.
    Lissoni P, Brivio F, Ardizzoia A, Tancini G, Barni S.
    Tumori; 1993 Dec 31; 79(6):401-4. PubMed ID: 8171739
    [Abstract] [Full Text] [Related]

  • 14. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
    Lissoni P, Brivio F, Barni S, Tancini G, Cattaneo G, Archili C, Conti A, Maestroni GJ.
    Anticancer Res; 1990 Dec 31; 10(6):1759-61. PubMed ID: 2285255
    [Abstract] [Full Text] [Related]

  • 15. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
    Lissoni P, Barni S, Tancini G, Mainini E, Piglia F, Maestroni GJ, Lewinski A.
    Oncology; 1995 Dec 31; 52(2):163-6. PubMed ID: 7854778
    [Abstract] [Full Text] [Related]

  • 16. Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin.
    Lissoni P, Pittalis S, Ardizzoia A, Brivio F, Barni S, Tancini G, Pelizzoni F, Maestroni GJ, Zubelewicz B, Braczkowski R.
    Support Care Cancer; 1996 Jul 31; 4(4):313-6. PubMed ID: 8829312
    [Abstract] [Full Text] [Related]

  • 17. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
    Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F.
    Nat Immun; 1998 Jul 31; 16(1):27-33. PubMed ID: 9789122
    [Abstract] [Full Text] [Related]

  • 18. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
    Lissoni P, Barni S, Ardizzoia A, Olivini G, Brivio F, Tisi E, Tancini G, Characiejus D, Kothari L.
    J Biol Regul Homeost Agents; 1993 Jul 31; 7(4):121-5. PubMed ID: 8023699
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.
    Lissoni P, Barni S, Cazzaniga M, Ardizzoia A, Rovelli F, Brivio F, Tancini G.
    Oncology; 1994 Jul 31; 51(4):344-7. PubMed ID: 8208518
    [Abstract] [Full Text] [Related]

  • 20. Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
    Lissoni P, Vigorè L, Rescaldani R, Rovelli F, Brivio F, Giani L, Barni S, Tancini G, Ardizzoia A, Viganò MG.
    J Biol Regul Homeost Agents; 1995 Jul 31; 9(4):155-8. PubMed ID: 8844341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.